PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Arthur D. Little Issues Insights on Genetic Testing’s Rapid Growth and Industry-Wide Impact

Arthur D. Little, a consultancy known for strategic thinking, innovative insight and expertise in technology-intensive and emerging industries, today issued a report covering the future of diagnostics and the growth potential of personal genetics services.
The report, “Future of Diagnostics – Personal Genetic Services Due for Explosive Growth,” identifies genetic services companies as disruptive forces that are consumerizing genomic testing and driving rapid transformation of a soon to become $18 billion global industry. Pharmaceutical companies, payers, providers and medtech companies will be impacted by the shift.
In an outcomes-based quality care environment, access to genetic information is critical to the effectiveness of treatments. According to the report, the emerging testing technology means manufacturers can enhance clinical trials, payers can be selective in authorizing treatment payouts, and patients can have more confidence in outcomes.
“Genetic analysis has moved from the domain of the healthcare practitioner to that of the consumer,” writes Craig Wylie, partner at Arthur D. Little. “We expect that a new, consumer-oriented industry will develop that will help individuals know and manage their risks…we also expect continued introduction of new assays going beyond mutation-based biomarkers to actionable biomarkers for an increasing number of conditions.”
The report includes recommendations on how key players should adjust to a consumer-centric genetic information age, as well as analysis of how genetic information enhances more precise care options when addressing life-threatening and incurable diseases.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026